Algert Global LLC acquired a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 76,204 shares of the biopharmaceutical company’s stock, valued at approximately $1,991,000. Algert Global LLC owned about 0.15% of Vanda Pharmaceuticals as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. United Services Automobile Association purchased a new stake in Vanda Pharmaceuticals during the 3rd quarter worth approximately $211,000. Crossmark Global Holdings Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $224,000. Meeder Asset Management Inc. increased its holdings in shares of Vanda Pharmaceuticals by 164.6% in the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 7,102 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $266,000. Finally, Piedmont Investment Advisors Inc. increased its holdings in shares of Vanda Pharmaceuticals by 1,255.3% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 12,089 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 11,197 shares during the last quarter. Institutional investors own 99.37% of the company’s stock.
In related news, SVP Gian Piero Reverberi sold 1,130 shares of the business’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $26.59, for a total transaction of $30,046.70. Following the completion of the transaction, the senior vice president now owns 136,569 shares in the company, valued at approximately $3,631,369.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Patrick Kelly sold 6,061 shares of the business’s stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $26.37, for a total value of $159,828.57. Following the transaction, the chief financial officer now owns 196,221 shares of the company’s stock, valued at approximately $5,174,347.77. The disclosure for this sale can be found here. Insiders have sold a total of 22,427 shares of company stock valued at $591,496 in the last 90 days. Insiders own 7.80% of the company’s stock.
VNDA has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price target for the company in a report on Saturday, November 17th. Citigroup boosted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, October 16th. Jefferies Financial Group initiated coverage on Vanda Pharmaceuticals in a report on Thursday, November 8th. They issued a “buy” rating and a $26.00 price target for the company. Oppenheimer set a $29.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, UBS Group downgraded Vanda Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 11th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $38.38.
NASDAQ:VNDA opened at $25.06 on Wednesday. Vanda Pharmaceuticals Inc. has a 12-month low of $13.88 and a 12-month high of $33.44. The company has a market cap of $1.33 billion, a P/E ratio of -71.60, a P/E/G ratio of 0.77 and a beta of 0.70.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Equities analysts forecast that Vanda Pharmaceuticals Inc. will post 0.21 earnings per share for the current fiscal year.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.